Head-To-Head Analysis: QHSLab (OTCMKTS:USAQ) vs. Solana (NASDAQ:HSDT)

Solana (NASDAQ:HSDT) and QHSLab (OTCMKTS:USAQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Risk and Volatility

Solana has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, QHSLab has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Earnings & Valuation

This table compares Solana and QHSLab”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$9.59 million	10.66	-$40.89 million	($109.67)	-0.02
QHSLab	$2.69 million	1.11	$460,000.00	$0.03	8.83

QHSLab has lower revenue, but higher earnings than Solana. Solana is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solana and QHSLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
QHSLab	15.60%	-27.74%	-6.98%

Analyst Ratings

This is a breakdown of current ratings for Solana and QHSLab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	1	1	2.50
QHSLab	0	0	0	0	0.00

Solana currently has a consensus target price of $3.50, indicating a potential upside of 100.00%. Given Solana’s stronger consensus rating and higher probable upside, equities analysts plainly believe Solana is more favorable than QHSLab.

Insider & Institutional Ownership

18.6% of Solana shares are held by institutional investors. 14.4% of Solana shares are held by insiders. Comparatively, 74.2% of QHSLab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Solana beats QHSLab on 8 of the 15 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.